Advanced Biological Laboratories SA (ABL) Receives CE Mark for It's TherapyEdge®
Published: May 29, 2013
Advanced Biological Laboratories (ABL) SA Announced That It Has Received CE Mark Certification to Market Its Innovative Patient Monitoring Application TherapyEdge in Europe and Other Markets That Recognize the CE Mark
LUXEMBOURG--(BUSINESS WIRE)-- TherapyEdge® enables medical professionals to capture and integrate all patient data and use specific decision support modules to access critical medical data that is coupled to knowledge databases and specific expert algorithm tailored to personalised medicine and treatment decisions.
“This is a significant milestone for ABL as it indicates our commitment to meeting the quality and safety standards required by the international healthcare marketplace,” ABL Vice-President for Research and Development Ronan Boulmé stated. “We have received an incredible level of interest in bringing our applications to Europe and other territories, and we can now move forward with our expansion plans.”
The CE Mark certification is for ABL’s three core offerings: TherapyEdge®, ViroScore® and DeepChek®. The latter two products received the CE Mark for in-vitro diagnostic (IVD) use earlier in 2012. The European medical device directives were revised in February 2012.
ABL's products are currently used by thousands of clinicians, virologists and researchers at hundreds of hospitals globally. These applications provide users with immediate and seamless desktop access anytime to vital live and historical patient data such as laboratory results, prescriptions and dispensing and clinical genotyping reports from Sanger and Next Generation Sequencing (NGS).
"The tremendous progresses and the continuous technology innovation, understanding physicians’ workflows or mapping how patients can be optimally managed made the story of ABL possible both in developing countries or Western world", said ABL CEO Dr Chalom Sayada. "We have revised our business proposal to make our products more widely available with flexible and cost-effective plans in this challenging economical environment: we offer affordable maximal yearly price per patient at 1 US$ that can be scaled-up for larger institutions in developing countries". “International commercialization is the exciting next step in expanding the availability of ABL's products, which enable more timely and accurate diagnosis and treatment and are already in strong demand globally, from Africa to the US”, added Dr Sayada.
About ABL, S.A.: Advanced Biological Laboratories (ABL), S.A., is a biotech company founded in 2000 as a spin-off from the European academic research center, CRP-Santé Luxembourg and in 2004, acquired the control of TherapyEdge, Inc. TherapyEdge is a biotech company spin-off from Triangle Pharmaceuticals, Inc., which was acquired by Gilead Sciences. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge®, ViroScore®, DeepChek® and VisibleChek®, which are used for data and patient management, monitoring and personalized reporting applications. In 2012, ABL’s products received CE-marking for In-Vitro Diagnostic use. ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. The clinical and biological outcomes aid in the generation of clinically meaningful genotyping reports for personalized healthcare. http://www.ablsa.com
Dr Chalom Sayada, +352 2638 8921
CEO ABL SA
Help employers find you! Check out all the jobs and post your resume.